Kendler DL, Bone HG, Massari F, et al. – Researchers conducted a phase 2, dose-finding study that included 167 postmenopausal women with low bone mass to assess the efficiency and safety of a second romosozumab course in women with high fracture risk. Participants received romosozumab or placebo (month 0–24) followed by placebo or denosumab (month 24–36), and then received a year of romosozumab (month 36–48). Following 12 months off-treatment, a second romosozumab course again resulted in rapid and large BMD gains. After denosumab, compared with initial treatment, BMD gains with romosozumab were smaller. Notably, during the second course, no new safety findings were observed.